Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.33 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222116 | 0.79 | ACHE (0.49) | ACHEKDM4EMAPT | |
| SCHEMBL4877854 | 0.79 | ACHE (0.44) | ACHE | |
| SCHEMBL14059398 | 0.79 | TDP1 (0.38) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL4873180 | 0.76 | ALDH1A1 (0.42) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL2166539 | 0.76 | NPC1 (0.44) | ACHEKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL2091407 | 0.74 | RXRA (0.48) | ALDH1A1MAPT | |
| SCHEMBL23461083 | 0.72 | ACHE (0.45) | ACHEKDM4EALDH1A1MEN1GAA | |
| SCHEMBL38662922 | 0.72 | ACHE (0.45) | ACHEKDM4EALDH1A1MEN1GAA | |
| SCHEMBL4875547 | 0.72 | SMN1; SMN2 (0.43) | ACHEKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL7223230 | 0.71 | MAOA (0.58) | KDM4EALDH1A1MEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | ACHE 3918/4885C5AR1 3571/4885PGR 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.